NXI Therapeutics

Executive Summary

NXI Therapeutics is a private Swiss biotechnology company founded in 2019 and headquartered in Basel, dedicated to developing next-generation immunotherapies for oncology and immunology. The company aims to overcome the limitations of current immunomodulatory treatments by focusing on enhanced specificity and safety. By leveraging novel mechanisms to modulate the immune system, NXI Therapeutics targets a wide range of cancers and autoimmune diseases where conventional therapies fall short. The company's innovative platform has the potential to address significant unmet medical needs, positioning it as a promising player in the immuno-oncology space. While still in early preclinical stages, NXI's Basel location provides access to a robust biotech ecosystem and top-tier talent. The company has yet to disclose its lead programs or raise significant disclosed funding, indicating it is likely operating in a confidential development phase. Nonetheless, its mission to pioneer safer and more effective immunotherapies aligns with industry trends, and management's ability to execute on its vision will be key to value creation.

Upcoming Catalysts (preview)

• H2 2026Series A Funding Round60% success
• 2027Lead Program Preclinical Data Release40% success
• H1 2027Collaboration or Licensing Deal30% success